计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G127944-50mg |
50mg |
现货 ![]() |
| |
| G127944-100mg |
100mg |
现货 ![]() |
| |
| G127944-250mg |
250mg |
现货 ![]() |
| |
| G127944-1g |
1g |
现货 ![]() |
| |
| G127944-5g |
5g |
现货 ![]() |
| |
| G127944-10g |
10g |
现货 ![]() |
| |
| G127944-25g |
25g |
现货 ![]() |
| |
| G127944-100g |
100g |
现货 ![]() |
|
| 别名 | 2'-脱氧-2',2'-二氟胞苷 |
|---|---|
| 英文别名 | 2'-Deoxy-2',2'-difluorocytidine | 2',2'-Difluorodeoxycytidine |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Gemcitabine |
| 生化机理 | 吉西他滨是一种广泛应用于临床和研究实验室的抗肿瘤药物。它是一种抗肿瘤药和抗代谢药。吉西他滨在细胞内转化为活性代谢物二氟脱氧胞苷二磷酸和三磷酸(dFdCDP、dFdCTP)。dFdCDP 可抑制核糖核苷酸还原酶,从而减少可用于 DNA 合成的脱氧核苷酸库;dFdCTP 可与 DNA 结合,导致 DNA 链终止和细胞凋亡。吉西他滨可抑制 BxPC-3 胰腺癌细胞株的增殖,IC50 为 0.06 μM。抗代谢物。诱导细胞凋亡。阻止胞嘧啶核苷酸转化为脱氧衍生物,并阻止胸苷核苷酸掺入 DNA 链。在体内具有抗肿瘤作用。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 核糖核苷酸还原酶催化亚基 M1 抑制剂;核糖核苷酸还原酶调节亚基 M2 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
2'-Deoxy-2',2'-difluorocytidine is an irreversible inactivator of R1 and R2 (ribonucleoside diphosphate reductase, RDPR) from Escherichia coli.An irreversible inactivator of bacterial ribonucleoside diphosphate reductase.Soluble in ethanol (~0.25 mg/ml), DMSO (15 mg/ml at 25 °C), DMF (~0.1 mg/ml), water (<1 mg/ml at 25 °C), and PBS pH 7.2 (~2 mg/ml). 2'-Deoxy-2',2'-difluorocytidine is an irreversible inactivator of R1 and R2 (ribonucleoside diphosphate reductase, RDPR) from Escherichia coli. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504753715 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
| INCHI | 1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 |
| InChi Key | SDUQYLNIPVEERB-QPPQHZFASA-N |
| Smiles | C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F |
| Isomeric SMILES | C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F |
| 关联CAS | 122111-03-9 |
| 分子量 | 263.2 |
| Reaxy-Rn | 11499718 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11499718&ln= |
| 溶解性 | DMSO 15 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 敏感性 | 对热敏感 |
| 比旋光度 | 74° (C=1,MeOH) |
| 熔点 | 217-222°C |
| 分子量 | 263.200 g/mol |
| XLogP3 | -1.500 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 2 |
| 精确质量Exact Mass | 263.072 Da |
| 单同位素质量Monoisotopic Mass | 263.072 Da |
| 拓扑极表面积Topological Polar Surface Area | 108.000 Ų |
| 重原子数Heavy Atom Count | 18 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 426.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07, GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H312: 皮肤接触有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H340: 可能导致遗传缺陷 H360: 可能损害生育力或未出生的孩子 H361: 怀疑破坏生育力或未出生的孩子 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P281: 根据需要使用个人防护设备。 P321: 特殊处理(请参阅此标签上的...)。 P302+P352: 如皮肤沾染:用水充分清洗。 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P318: 如果暴露或担心,请就医。 P317: 寻求紧急医疗救助。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。 |
| Merck Index | 4386 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 | |
| 分析证书 | G127944 |
¥139.90
| 1. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, Pommier Y. (2002) Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.. Clin Cancer Res, 8 (8): (2499-504). [PMID:12171875] |
| 2. Dongchao Xu, Ajuan Liu, Qiang Liu, Hongchen Zhang, Mengyao Tian, Ying Bian, Xiaofeng Zhang, Meidan Ying, Hongzhang Shen. (2023) Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. BIOCHEMICAL PHARMACOLOGY, 217 (115810). [PMID:37717690] [10.1016/j.bcp.2023.115810] |
| 3. Yifan Luo, Chao Li, Yiwen Zhang, Peixin Liu, Hongyi Chen, Zhenhao Zhao, Yu Wang, Zheng Zhou, Haolin Song, Boyu Su, Chufeng Li, Xuwen Li, Tongyu Zhang, Haoyu You, Yuxing Wu, Zonghua Tian, Shilin Zhang, Yun Guo, Hongrui Fan, Qinjun Chen, Chen Jiang, Tao Sun. (2023) Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Acta Biomaterialia, [PMID:37276955] [10.1016/j.actbio.2023.05.047] |
| 4. Nan Zhang, Junwei Zhang, Weiqi Cui, Deqiao Wu, Jingxian Zhang, Bo Wei, Lingbo Qu, Xia Xu. (2023) Artemisia argyi H.Lév. & Vaniot essential oil induces ferroptosis in pancreatic cancer cells via up-regulation of TFR1 and depletion of γ-glutamyl cycle. FITOTERAPIA, 168 (105522). [PMID:37169131] [10.1016/j.fitote.2023.105522] |
| 5. Zhuo Yao, Qida Hu, Piaopiao Jin, Bowen Li, Yong Huang, Fu Zhang, Meng Wang, Junming Huang, Jing Huang, Shiyi Shao, Xinyu Zhao, Yuan Ping, Tingbo Liang. (2023) A Self-Assembly Combined Nano-Prodrug to Overcome Gemcitabine Chemo-Resistance of Pancreatic Tumors. ADVANCED FUNCTIONAL MATERIALS, (2214598). [10.1002/adfm.202214598] |
| 6. Fu Zhang, Zhuo Yao, Piaopiao Jin, Mengqiu Xu, Qida Hu, Yuxuan Chen, Risheng Que, Tingbo Liang. (2023) A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator. Biomedical Materials, 18 (3): (35010). [PMID:36990101] [10.1088/1748-605X/acc8ac] |
| 7. Fu Zhang, Qida Hu, Bowen Li, Yong Huang, Meng Wang, Shiyi Shao, Honglin Tang, Zhuo Yao, Yuan Ping, Tingbo Liang. (2023) A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors. JOURNAL OF CONTROLLED RELEASE, 354 (835). [PMID:36627026] [10.1016/j.jconrel.2023.01.007] |
| 8. Hao Chi, Sheng Tian, Xiu Li, Yuchu Chen, Qiumin Xu, Qixiao Wang, Wenwan Shi, Michael Adu-Frimpong, Shanshan Tong. (2023) Construction of lipid raft-coupled agarose gels as bioaffinity chromatography materials and validation with tropomyosin-related kinase A-targeted drugs. JOURNAL OF CHROMATOGRAPHY A, 1691 (463803). [PMID:36731332] [10.1016/j.chroma.2023.463803] |
| 9. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang. (2022) Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (12): (6597). [PMID:35743042] [10.3390/ijms23126597] |
| 10. Yuting Zhu, Shanhao Han, Jianhui Li, Hongwei Gao, Bo Dong. (2022) Aqueous Extract of Sea Squirt (Halocynthia roretzi) with Potent Activity against Human Cancer Cells Acts Synergistically with Doxorubicin. Marine Drugs, 20 (5): (284). [PMID:35621935] [10.3390/md20050284] |
| 11. Chen Ting-ting, Yuan Ming-ming, Tao Yu-mei, Ren Xiao-yan, Li Sufen. (2022) Engineering of Self-assembly Polymers Encapsulated with Dual Anticancer Drugs for the Treatment of Endometrial Cancer. JOURNAL OF CLUSTER SCIENCE, 33 (6): (2661-2671). [10.1007/s10876-021-02175-5] |
| 12. Yingjie Kong, Yeneng Dai, Dashan Qi, Wenyu Du, Haiyang Ni, Fan Zhang, Honghai Zhao, Qingming Shen, Meixing Li, Quli Fan. (2021) Injectable and Thermosensitive Liposomal Hydrogels for NIR-II Light-Triggered Photothermal-Chemo Therapy of Pancreatic Cancer. ACS Applied Bio Materials, 4 (10): (7595–7604). [PMID:35006703] [10.1021/acsabm.1c00864] |
| 13. Xiaoyu Xu, Zishan Zeng, Xin Ding, Ting Shan, Qiuxing Liu, Meixu Chen, Jie Chen, Meng Xia, Yuanfeng He, Zeqian Huang, Yanjuan Huang, Chunshun Zhao. (2021) Reactive oxygen species-activatable self-amplifying Watson-Crick base pairing-inspired supramolecular nanoprodrug for tumor-specific therapy. BIOMATERIALS, 277 (121128). [PMID:34537502] [10.1016/j.biomaterials.2021.121128] |
| 14. Cui Jing, Guo Yao, Wu Heshui, Xiong Jiongxin, Peng Tao. (2021) Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. MOLECULAR MEDICINE, 27 (1): (1-16). [PMID:33849427] [10.1186/s10020-021-00300-8] |
| 15. Feng Fan, Lijun Jin, Lihua Yang. (2021) pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer. ACS Applied Materials & Interfaces, 13 (11): (12824–12835). [PMID:33689289] [10.1021/acsami.0c16576] |
| 16. Xin Zhang, Jiapeng Xu, Ronglin Yan, Yu Zhang, Zunqi Hu, Hongbing Fu, Qing You, Qingping Cai, Dejun Yang. (2020) FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway. Aging-US, 12 (8): ( 6808–6822). [PMID:32291380] [10.18632/aging.103044] |
| 17. Jing Dai, Yiqun Wang, Dinghao Wu, Fengju Wan, Yi Lu, Na Kong, Xiuchun Li, Jinkang Gong, Shengjie Ling, Yuan Yao. (2020) Biointerface mediates cytoskeletal rearrangement of pancreatic cancer cell and modulates its drug sensitivity. Colloid and Interface Science Communications, 35 (100250). [10.1016/j.colcom.2020.100250] |
| 18. Yan Liang, Jing Zhang, Baocheng Tian, Zimei Wu, Darren Svirskis, Jingtian Han. (2020) A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells. International Journal of Nanomedicine, [PMID:32103941] [10.2147/IJN.S226249] |
| 19. Lin Xiao-mian, Luo Wu, Wang Heng, Li Rong-zhen, Huang Yi-shan, Chen Lian-kuai, Wu Xiao-ping. (2019) The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 10 (836). [PMID:31440159] [10.3389/fphar.2019.00836] |
| 20. Liu Yue, Lu Shan, Zhao Liang, Dong Xin, Zhu Zhenyu, Jin Yongsheng, Chen Haisheng, Lu Feng, Hong Zhanying, Chai Yifeng. (2018) Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 410 (14): (3325-3335). [PMID:29651531] [10.1007/s00216-018-0996-8] |
| 21. Tingyu Yu, Jiao Lin, Jin Zhao, Wei Huang, Lingwen Zeng, Zhiyuan Fang, Ning Xu. (2017) A simple in vitro tumor chemosensitivity assay based on cell penetrating peptide tagged luciferase. PLoS One, 12 (11): (e0186184). [PMID:29125836] [10.1371/journal.pone.0186184] |
| 22. Peng-fei Liu, Yan-wei Cao, Shu-dong Zhang, Yang Zhao, Xiao-guang Liu, Hao-qing Shi, Ke-yao Hu, Guan-qun Zhu, Bo Ma, Hai-tao Niu. (2015) A bladder cancer microenvironment simulation system based on a microfluidic co-culture model. Oncotarget, 6 (35): ( 37695–37705). [PMID:26462177] [10.18632/oncotarget.6070] |
| 23. Hong Jiawei, Xian Shiyun, Zheng Shusen, Wang Hangxiang, Jiang Donghai. (2024) Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancer. Nano Research, (1-12). [10.1007/s12274-024-6860-6] |
| 24. Zheng Rongji, Guan Tian, Hong Chaoqun, Yao Yao, Fang Yutong, Huang Wei, Chen Chunfa, Zeng Huancheng, Huang Jiman, Lin Hui, Chen Bingfeng, Zhang Rendong, Chen Dongmei, Ding Zhechun, Zeng Haoyu, Wu Jundong. (2024) C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration. Journal of Translational Medicine, 22 (1): (1-9). [PMID:39174945] [10.1186/s12967-024-05542-8] |
| 25. Qida Hu, Fu Zhang, Bowen Li, Piaopiao Jin, Junming Huang, Zhuo Yao, Xinyu Zhao, Shiyi Shao, Meng Wang, Yuan Ping, Tingbo Liang. (2025) Engineered a Gemcitabine Nano-Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics. Small, (2410629). [PMID:40007057] [10.1002/smll.202410629] |
| 26. Yuanxin Pian, Yan Hao, Yuxin Guo, Shiqi Wu, Saijiao Tang, Jiaqi Li, Xinya Lu, Xiaoya Sun, Zhaowen Tan, Tianyu Zhu, Yuxiang Tang, Defeng Xu, Hang Hu. (2025) Exploration of using α-crocin for drug encapsulation and delivery. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 106 (106716). [10.1016/j.jddst.2025.106716] |
| 27. Qinglian Hu, Jiayu Feng, Lulu Qi, Yuanxiang Jin. (2024) Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer. ACS Applied Materials & Interfaces, 16 (45): (61583-61598). [PMID:39480275] [10.1021/acsami.4c10404] |
| 28. Lihong Chen, Zijia Zhao, Rominah Onintsoa Diarimalala, Zhongwei Chen, Yu Wang, Taozhu Zhan, Yanchao Zhao, Chunhui Ma, Xingyue Wang, Chenqi Zhao, Zicheng Xiao, Kanghong Hu, Pingfan Wu. (2024) Tris-functionalized polyoxotungstovanadate-mediated antitumor efficacy involves multiple cell death pathways. CHEMISTRY & BIODIVERSITY, (e202301898). [PMID:38369765] [10.1002/cbdv.202301898] |
| 29. Hongzi Wu, Bowen Li, Jichun Shao, Qingquan Kong. (2024) Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, (132019). [PMID:38729498] [10.1016/j.ijbiomac.2024.132019] |